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Abstract
CDK5 regulatory subunit associated protein 3 (CDK5RAP3) is a novel activator of PAK4 and processes important pro-
metastatic function in hepatocarcinogenesis. However, it remains unclear if there are other mechanisms by which
CDK5RAP3 promotes HCC metastasis. Here, we showed that in CDK5RAP3 stable knockdown SMMC-7721 HCC cells, p14ARF
tumor suppressor was upregulated at protein and mRNA levels, and ectopic expression of CDK5RAP3 was found to repress
the transcription of p14ARF. Using chromatin immunoprecipitation assay, we demonstrated that CDK5RAP3 bound to p14ARF
promoter in vivo. Furthermore, knockdown of p14ARF in CDK5RAP3 stable knockdown HCC cells reversed the suppression of
HCC cell invasiveness mediated by knockdown of CDK5RAP3. Taken together, our findings provide the new evidence that
overexpression of CDK5RAP3 promotes HCC metastasis via downregulation of p14ARF.
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Introduction
CDK5RAP3 (also called C53/LZAP) was first identified as
a binding partner of cyclin-dependent kinase 5 (CDK5) activator,
p35nck5a, in yeast two-hybrid screening [1]. Several studies have
investigated the potential roles of CDK5RAP3 in carcinogenesis,
but so far its definite roles remain controversial. CDK5RAP3 has
been found to promote apoptosis induced by genotoxic stress in
HeLa cells by triggering G2/M arrest [2]. In addition,
CDK5RAP3 has been proposed to be a tumor suppressor because
it inhibits the NF-kB cell survival pathway and its protein level is
significantly underexpressed in head and neck squamous cell
carcinomas [3]. CDK5RAP3 can interact with a well-known
tumor suppressor, namely alternate reading frame (p14ARF), by
which stabilizes and promotes the transcription activity of p53 [4];
yet, the role of this interaction in carcinogenesis has not been
explored.
More recently, we demonstrated that CDK5RAP3 is frequently
overexpressed in human HCCs and contributes to HCC
metastasis by activating PAK4 [5]. CDK5RAP3 has 2 putative
LXXLL motifs, which are the signature motifs for transcriptional
co-regulators, mediating the binding on nuclear receptors. In
addition, CDK5RAP3 has a leucine zipper domain, which is
a structural motif for protein dimerisation and is commonly found
in proteins involving in gene expression. Previous study has shown
that CDK5RAP3 can associate with a nuclear co-activator, cAMP
response element-binding protein (CREB)-binding protein (CBP)
[6], suggesting that CDK5RAP3 may also function as a transcrip-
tional co-activator/repressor. Here, we provide evidences that
CDK5RAP3 is a putative transcriptional suppressor of p14ARF and
overexpression of CDK5RAP3 promotes to the metastasis of HCC
by downregulating p14ARF. Thus inhibition of CDK5RAP3 can
potentially be used to restore the expression of the important
tumor suppressor p14ARF expression, providing new molecular
targets for the therapeutic intervention in HCC and possibly other
cancers.
Materials and Methods
Antibodies
Anti-CDK5RAP3 antibody was reported previously [5]. Rabbit
anti-GFP (FL), mouse anti-Myc (9E10), rabbit anti-Myc (A-14),
mouse anti-p53 (DO-1), mouse anti-phospho-p53 (S15) and rabbit
anti-MDM2 (C-18) were purchased from Santa Cruz Biotechnol-
ogy. Rabbit anti-p14ARF was purchased from Abcam. Mouse anti-
b-actin (AC15) was purchases from Sigma-Aldrich.
Plasmids
The p14ARF promoter luciferase reporter construct, pGL3-
p14ARF-luc, and the truncation mutants generated from pGL3-
p14ARF-luc were generous gifts from Dr. Kiyoshi Ohtani [7].
Plasmid expressing Myc-CDK5RAP3 was reported previously [5]
and pEGFP-p14ARF was constructed by subcloning full length of
p14ARF cDNA fragment (clone IMAGE: 6173590) into pEGFP
vector (Clontech, Palo Alto, CA). HA-E2F1 expression plasmid
was obtained from Addgene (Sellers et al., 1998, Addgene plasmid
10736).
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Cell Culture
Human hepatoma cell line HepG2 and monkey kidney
fibroblast cell line COS7 were purchased from ATCC. Human
HCC cell line SMMC-7721 was gift from Shanghai Institute of
Biochemistry and Cell Biology, Chinese Academy of Sciences [8].
Cells were maintained in DMEM high glucose (Life Technologies,
Rockville, MD) supplemented with 1 mM sodium pyruvate and
10% heat-inactivated FBS (JRH Biosciences, Lenexa, KS). Cells
were transfected with DNA constructs using LipofectAMINE 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol.
siRNA Oligonucleotide Transfection
CDK5RAP3 small interfering RNA (siRNA) duplex was
transfected into cells as described [5]. siRNA duplex targeting
p14ARF 59-GCGGAAGGUCCCUCAGACAUU-39 (sense strand)
and non-targeting siRNA duplex negative control, 59-UAAGG-
CUAUGAAGAGAUAC-39 (sense strand) were purchased from
Dharmacon, Inc, Lafayette, CO.
Reverse Transcription-PCR (RT-PCR)
Quantitative real-time PCR (qPCR) was performed as described
[9]. The sequence of taqman probes (Applied Biosystems) for
CDK5RAP3 and p14ARF are 59-AGGAAAGATGGAGGACCAT-
CAGCAC-39 and 59-TAGAAGACCAGGTCATGAT-
GATGGG-39 respectively; cellular 18S rRNA was used as an
internal control.
Cell Migration and Invasion Assay
Transwell assay and invasion assay were performed as described
[10,11], respectively. The cells were allowed to migrate for
16 hours and invade for 24 hours, respectively. A total of 5 fields
were counted for each filter. The experiments were performed
three times independently.
Confocal Microscopy
Cells were fixed with 4% paraformaldehyde and permeabilized
with 0.2% Triton-X100 [9]. Images were captured by Carl Zeiss
LSM510 (HKU Faculty core facility).
Luciferase Reporter Assay
Cells cultured in 24-well plates were transfected with Myc-
CDK5RAP3 in addition to 100 ng of p14ARF-luc or p53-luc, and
10 ng of pRL-CMV. Luciferase activity was measured using the
Dual-LuciferaseH Reporter Assay System (Promega, Madison,
WI), and light emission was quantified using a microplate
luminometer (MicroLumat PLUS, Perkin-Elmer, Shelton, CT).
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed
using a ChIP Assay Kit (Millipore, Billerica, MA). CDK5RAP3
stable overexpression clone #2 HepG2 cells (16107) were used for
the assay.
Statistical Analysis
Student’s t-test was used for statistical analysis of data. Tests
were considered significant with P,0.05.
Results
Knockdown of CDK5RAP3 Upregulated p14ARF
Our previous study demonstrated that overexpression of
CDK5RAP3 promoted HCC metastasis by activation of PAK4
[5]. However, as CDK5RAP3 is associated with tumor suppressor,
p14ARF [4], we wonder if p14ARF also plays a role in CDK5RAP3-
mediated HCC formation. To investigate if CDK5RAP3 regulates
p14ARF, Western blotting was performed to detect the protein level
of p14ARF in CDK5RAP3 stable knockdown SMMC-7721 cell
lines [5]. Interestingly, the stable knockdown of CDK5RAP3 in
SMMC-7721 cells resulted in an upregulation of p14ARF (Fig. 1a).
However, no significant difference was observed for the other
components of the p14ARF/HDM2/p53 pathway, such as HDM2
Figure 1. Regulation of p14ARF localization and protein expression by CDK5RAP3. (a) The p14ARF and CDK5RAP3 protein levels in stable
CDK5RAP3 knockdown SMMC-7721 clones (shCDK5RAP3#1 and #2), vector control and parental cells [5] were compared by Western blotting using
indicated antibodies, respectively. (b) The stable CDK5RAP3 knockdown SMMC-7721 (shCDK5RAP3#2) and vector control cells were treated with
100 mg/ml cycloheximide or DMSO (vehicle), and harvested at the indicated time points. p14ARF and b-actin protein levels were determined by
Western blotting. V: DMSO treatment. Top: Western blotting; bottom: quantification of p14ARF protein level.
doi:10.1371/journal.pone.0042210.g001
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and p53, suggesting that the upregulation of p14ARF may be
independent of the protein interaction between HDM2 and
p14ARF (Fig. 1a). Since the protein level of p14ARF is largely
regulated by protein degradation [12], the possibility that
CDK5RAP3 might enhance the turnover rate of p14ARF was
examined. By treatment with cycloheximide, an inhibitor of
protein synthesis, we observed that the protein degradation rate of
p14ARF in the CDK5RAP3 stable knockdown clone #2 was
slower than that of the vector control cells in the first six hours of
treatment, but they reached to a similar rate after 24 hours,
suggesting that CDK5RAP3 only has a very transient effect on the
protein stability of p14ARF (Fig. 1b).
CDK5RAP3 Repressed p14ARF Transcription in HCC Cells
To further understand how CDK5RAP3 might enhance the
expression of p14ARF, and as CDK5RAP3 contains structural
motifs suggested to be a transcriptional regulator, we examined if
CDK5RAP3 regulates p14ARF transcriptionally. p14ARF mRNA
level was found to be upregulated in the CDK5RAP3 stable
knockdown SMMC-7721 clones (Fig. 2a). Consistently, down-
regulation of p14ARF mRNA expression was also observed in two
CDK5RAP3 stable overexpressing HepG2 clones that we
established previously [5] (Fig. 2b). To further understand the
mechanism by which CDK5RAP3 regulates p14ARF transcription,
luciferase reporter assay was performed to determine the effect of
CDK5RAP3 on p14ARF promoter transcription activity. A p14ARF
promoter luciferase reporter plasmid contained the p14ARF pro-
moter region 736 base pair (bp) upstream from the transcription
start site was used for the assay [7]. As shown in Fig. 2c, ectopic
expression of CDK5RAP3 significantly suppressed the p14ARF
promoter luciferase activity in a dose-dependent manner in
SMMC-7721 HCC cells (Fig. 2c). Similar result was also observed
in HepG2 cell line, suggesting that CDK5RAP3 can transcrip-
tionally repress the expression of p14ARF (Fig. 3c). To further
understand how CDK5RAP3 suppresses p14ARF transcription, we
used luciferase reporters carrying a series of truncation mutants of
the p14ARF promoter to map the region responsible for the
CDK5RAP3 suppression. As shown in Fig. 2d, CDK5RAP3
suppressed the luciferase activity of the p14ARF promoter in the
constructs of 2736, 2327 and 2231 to roughly 50%, but not in
the construct of 2150, suggesting that nucleotides 2231 to 2151
are important for CDK5RAP3 suppression.
CDK5RAP3 Bound to Endogenous p14ARF promoter
As the ability of CDK5RAP3 to attenuate the p14ARF promoter
activation and to repress endogenous p14ARF expression were
demonstrated, we further investigates whether CDK5RAP3 binds
to endogenous p14ARF promoter by chromatin immunoprecipita-
tion (ChIP) assay using CDK5RAP3 stable overexpressing HepG2
cells [5]. Two sets of primers that has been reported previously
were used to amplify p14ARF promoter regions (21888 to 21659
and 248 to +267) [13]. As shown in Fig. 2d, immunoprecipitated
with anti-CDK5RAP3 antibody significantly enriched the DNA
fragments containing the promoter region of p14ARF, as compared
with the no antibody control (Fig. 2e), strongly indicating that
CDK5RAP3 can direct bind to the p14ARF promoter.
Nuclear Localization of CDK5RAP3 was Important for the
p14ARF Transcriptional Repressive Activity
To map out whether specific region of CDK5RAP3 is required
for the repression of p14ARF transcription, a panel of deletion and
LXXLL point mutation mutants of CDK5RAP3 was generated.
To rule out the possibility that these mutants are unstable within
the cells, Western blot analysis was performed to confirm the
expression of these mutants. The result showed that all the
mutants expressed at similar levels in cells, apart from the 1–217
deletion mutant, which expressed at a lower level (Fig. 3b). To
examine the transcriptional suppressive activity of these mutants,
luciferase reporter assay was performed. Mutation of both LXXLL
motifs on CDK5RAP3 to LXXAA (L117AL118A/L475AL476A)
and a 1–362 deletion mutant of CDK5RAP3 was much less potent
in repressing the p14ARF promoter activity (Fig. 3c), as compared to
the full length protein. Similar result of double point mutant was
also obtained for single LXXLL/LXXAA mutants (data not
shown). However, for the deletion mutants, including 1–256, 255–
506 and 434–506, all of them had completely lost their repressive
activity on p14ARF promoter (Fig. 3c). This result suggests that the
overall integrity of CDK5RAP3 protein may be important for the
repression activity. Surprisingly, the 1–217 mutant, which was
relatively unstable, did not repress, but activates the p14ARF
promoter activity (Fig. 3c). More interestingly, among the panel of
mutants, the a.a. 1–217 mutant was the only mutant that did not
localize to the nucleus (Fig. 3d), indicating that the nuclear
localization of CDK5RAP3 may be important for the its repressive
activity on p14ARF promoter and protein stability (Fig. 3d). Taken
together, our data indicate that CDK5RAP3 repressed p14ARF
promoter activity in HCC cells.
CDK5RAP3 had no Effect on E2F1-mediated p14ARF
Promoter Transactivation
p14ARF is the upstream activator for p53 activity as it can
abrogate the MDM2-mediated degradation of p53 by inhibiting
MDM2 [14,15], we wonder if regulation of p14ARF expression by
CDK5RAP3 affects p53 transactivation activity. Using p53
luciferase reporter assay, we showed that CDK5RAP3 did not
affect the p53 promoter activity (Fig. 4a), indicating that
CDK5RAP3 may not have an effect on p14ARF-mediated
regulation of p53 in HCC cells. To examine if CDK5RAP3
represses the p14ARF via regulating the transcriptional activator of
p14ARF, E2F1, luciferase reporter assays were performed by
overexpressing Myc-tagged CDK5RAP3 and HA-tagged E2F1
in HepG2 cells. Although ectopic expression of E2F1 caused
a dose-dependent activation of p14ARF luciferase reporter (Fig. 4b
lane 3 to 5), co-expression of CDK5RAP3 did not affect the E2F1-
mediated p14ARF transactivation (Fig. 4b lane 6 to 8). Therefore,
the mechanism by which CDK5RAP3 downregulates p14ARF
promoter transcription is most likely independent of E2F1.
Knockdown of p14ARF Reversed the Suppression of Cell
Migration and Invasiveness in CDK5RAP3 Knockdown
cells
Since evidence has demonstrated that mouse homolog of
p14ARF, p19ARF inhibited HCC cell invasion [16], we speculate
that the upregulation of p14ARF in CDK5RAP3 stable knockdown
HCC clones may cause the decrease in migration of these stable
clones [5]. To elucidate whether p14ARF plays a role in
CDK5RAP3-mediated regulation of invasiveness in HCC cells,
we examine the effect of silencing p14ARF in CDK5RAP3 stable
knockdown clones motility. The specific knockdown of p14ARF by
two independent p14ARF siRNA was confirmed by Western
blotting (Fig. 5a). Then we asked if the effect of knockdown of
CDK5RAP3 on cell motility and invasiveness could be restored by
knockdown of p14ARF. As shown in Fig. 5b, knockdown of p14ARF
in CDK5RAP3 stable knockdown SMMC-7721 cells significantly
increased the number of migrated cells as compared to the control
siRNA, suggesting that loss of p14ARF reversed the suppression of
CDK5RAP3 Represses p14ARF
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Figure 2. Suppression of endogenous expression of p14ARF by CDK5RAP3. (a) The p14ARF and CDK5RAP3 mRNA expression in stable
CDK5RAP3 knockdown SMMC-7721 stable clones was determined by Quantitative real-time PCR (qPCR). Data was analyzed by comparative Ct
method. Band intensity was analyzed using AlphaEasePC software and normalized with b-actin. Results were mean of three independent
experiments. *, P,0.005, Student’s t-test. (b) Similar to (a), the CDK5RAP3 stable expressing HepG2 clones (CDK5RAP3#1 and#2), vector control and
parental cells were used for qPCR assay. Results were mean of three independent experiments. *P,0.04 and **P,0.02 compared with vector control,
CDK5RAP3 Represses p14ARF
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cell migration. Consistently, the invasiveness of CDK5RAP3
stable knockdown SMMC-7721 cells was also significantly re-
stored in p14ARF siRNA knockdown cells (Fig. 5b). Thus these
results demonstrated that overexpression of CDK5RAP3 can
promote HCC cell metastasis through downregulation of p14ARF.
Discussion
CDK5RAP3 has 2 putative LXXLL motifs, which are the
signature motifs for transcriptional co-regulators, mediating the
binding on nuclear receptors. Previous study has shown that
CDK5RAP3 can associate with a nuclear co-activator, cAMP
response element-binding protein (CREB)-binding protein (CBP),
suggesting that CDK5RAP3 may also function as a transcriptional
co-activator/repressor. Recently, CDK5RAP3 is shown to promote
HCC metastasis by activating PAK4 kinase activity [5]. In this
study, we provide evidence for a novel mechanism by which
CDK5RAP3 promotes HCC metastasis by downregulating tumor
suppressor p14ARF transcriptionally. Our data demonstrated that
loss of CDK5RAP3 drastically enhanced the expression of p14ARF
(Fig. 1a and 2a) at both protein and mRNA levels in HCC cells.
This notion is supported by three line of evidence. First, we
Student’s t-test. (c) The CDK5RAP3 expression construct and p14ARF luciferase reporter, pGL3-p14ARF were co-transfected into SMMC-7721 cells for
dual-luciferase reporter assay. Results represent mean 6SD for triplicate wells. *, P,0.05 compared with vector control, Student’s t-test. (d) Similar to
(c), luciferase reporters carrying truncation mutants of the p14ARF promoter, CDK5RAP3 expression construct (0.3 mg) and vector (0.3 mg) were used
for dual-luciferase reporter assay. Results represent mean 6SD for triplicate wells. *, P,0.02 compared with vector control, Student’s t-test. (e)
CDK5RAP3 bound p14ARF promoter by performing chromatin immunoprecipitation (ChIP) analysis on CDK5RAP3 stable overexpression clone #2
HepG2 cells (16107). Input (IN) and no antibody control (No Ab) were included. Error bars: mean 6SD.
doi:10.1371/journal.pone.0042210.g002
Figure 3. Nuclear localization of CDK5RAP3 was important for the suppression of p14ARF promoter activity. (a) Schematic diagram of
CDK5RAP3 mutants (b) Western blotting showing the expression levels of CDK5RAP3 mutants overexpressed in HepG2. Protein lysates from reporter
assay were used for Western blotting probed with anti-Myc antibody. (c) Dual luciferase reporter was performed by co-transfection of CDK5RAP3
mutants with p14ARF-luc reporter in HepG2. Results were mean of three independent experiments, with promoter activity of vector control set as
100%. *, P,0.05 and **, P,0.005 compared with vector control, Student’s t-test. (d) Confocal images of wild type (WT) and the indicated deletion
mutants of Myc-CDK5RAP3.
doi:10.1371/journal.pone.0042210.g003
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Figure 4. CDK5RAP3 transcriptionally regulated p14ARF in a E2F1 independent manner. (a) CDK5RAP3 was co-transfected with p53-
responsive element reporter for luciferase assay in HepG2 cells. Results represent mean6SD for triplicate wells. *, P,0.05, **, P,0.005 compared with
vector control, Student’s t-test. (b) Expression constructs of CDK5RAP3 was co-transfected with HA-E2F1 and p14ARF-luc reporter for luciferase assay
in HepG2 cells. Results represent mean 6SD for triplicate wells. *, P,0.005 compared with vector control, Student’s t-test.
doi:10.1371/journal.pone.0042210.g004
Figure 5. Knockdown of p14ARF reversed the suppression of cell migration and invasiveness in CDK5RAP3 knockdown HCC cells. (a)
The CDK5RAP3 stable knockdown SMMC-7721 cells were transfected with p14ARF or control siRNA. Top,Western blotting showing p14ARF knockdown
in cells; bottom, The bar chart showed the quantitation of migrated cells in three independent experiment (*, P= 0.005, Student’s t-test).
Representative photomicrographs were shown. (b) Similar to a), but invasion assay were performed. The bar chart showed the quantitation of the
invaded cells in three independent experiment (*, P= 0.05, Student’s t-test).
doi:10.1371/journal.pone.0042210.g005
CDK5RAP3 Represses p14ARF
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observed that upregulation of p14ARF transcripts was observed in
CDK5RAP3 stable knockdown HCC clones, whereas down-
regulation of p14ARF transcripts was observed in CDK5RAP3
stable overexpressing HCC clones. Second, using p14ARF promoter
luciferase reporter assay, we showed that forced expression of
CDK5RAP3 repressed the p14ARF promoter transcriptional
activity in a dose-dependent manner (Fig. 2c). Third, using ChIP
analysis, CDK5RAP3 was found to bind directly to p14ARF
promoter region (Fig. 2e), indicating that CDK5RAP3 may
directly regulate the p14ARF promoter activity. Indeed,
CDK5RAP3 has recently been reported to repress cyclin D1
transcription [17] and NF-kB transcriptional activity [18], further
supporting the role of CDK5RAP3 as a transcriptional co-
regulator. Taken together, these data indicated that CDK5RAP3
is a putative negative transcriptional regulator of p14ARF. As for
how CDK5RAP3 can repress the p14ARF promoter activity, we
find that the overall integrity of the protein may be important. It is
because all the truncation of CDK5RAP3 resulted in a completely
lost of repressive activity of CDK5RAP3, apart from 1–362 mu-
tant, which retains a moderate repressive activity (Fig. 3b).
Interestingly, our data also suggested that the nuclear localization
of CDK5RAP3 is important for its repressor activity (Fig. 3d) and
this supports our hypothesis that CDK5RAP3 regulates the
transcription of p14ARF via direct binding to p14ARF promoter,
as revealed by our ChIP analysis (Fig. 2e).
p14ARF is one of the upstream activators for p53 as it can
abrogate the MDM2-mediated degradation of p53 by inhibiting
MDM2 [14,15]. However, in CDK5RAP3 stable knockdown
HCC cells, we found that p53 and phospho-p53 (Ser15) levels
remained unchanged (Fig. 1a). Furthermore, overexpression of
CDK5RAP3 in HCC cells did not seem to have a significant
impact on p53 transactivation activity (Fig. 4a). Thus these results
indicate that CDK5RAP3 did not play a significant role in
regulating p53 via p14ARF in HCC cells. Actually, this observation
is in consistent with our previous result showing that the
transforming ability of CDK5RAP3 on HCC cells were p53-
independent as CDK5RAP3 knockdown reduced proliferation
rate and colonies formed in p53-defective PLC/PRF/5 HCC cell
line [5].
The mechanism by which overexpression of CDK5RAP3
enhances HCC metastasis is not completely understood. Here,
we propose that via the downregulation of p14ARF, CDK5RAP3
can enhance the invasiveness of HCC cells. To this end, we used
siRNA to specifically knock down p14ARF in SMMC-7721 cells
with CDK5RAP3 stable knockdown and showed that the loss of
p14ARF significantly promoted the motility and invasiveness of
HCC cells (Fig. 5). Previous studies have shown that mouse
homolog of p14ARF, p19ARF can inhibit the invasion of HCC cells
by binding to C-terminal binding protein (CtBP) [16]. Interest-
ingly, while CtBP binds to a.a. residues 42 to 54 of p14ARF [16],
CDK5RAP3 binds to a.a. residues 1 to 64 of p14ARF [4],
suggesting that the p14ARF binding region of CtBP and
CDK5RAP3 may indeed overlap. Thus it is conceivable that
CDK5RAP3 may sequester the binding of p14ARF to CtBP and
release the free CtBPs to promote HCC cell invasion. Further
experiment is currently undergoing to test this hypothesis.
Collectively, the underlying mechanism for the transcriptional
regulation of p14ARF by CDK5RAP3 still not completely clear, and
whether CDK5RAP3 regulates generally on INK4a/p14ARF/INK4b
locus or specifically on p14ARF requires further investigation. As
CDK5RAP3 has been reported to interact with CBP [19], a co-
activator for CREB, it remains to be determined whether
CDK5RAP3 regulates p14ARF promoter by modulating CBP/
CREB activity. In HCC, silencing of the p14ARF promoter through
hypermethylation is frequently observed [20]. However, our data
suggest that p14ARF transcription can also be repressed by
upregulation of CDK5RAP3. In addition, our data provide
a novel insight by which overexpression of CDK5RAP3 can
enhance HCC metastasis via negatively regulating p14ARF. As
a result, inhibition of CDK5RAP3 can potentially be used to
restore the expression of this important tumor suppressor
expression, providing new molecular targets for the therapeutic
intervention in HCC.
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